Positive data from early trial of candidate malaria vaccine announced

A year-long trial involving 450 children in Burkina Faso found the vaccine (R21/Matrix-M), developed by scientists at the University of Oxford, had 77% efficacy when used with a high dose of adjuvant and 74% when used with a low dose of adjuvant.

Source:

Reuters Health